Navigation Links
InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
Date:9/24/2008

-responders encouraged InterMune and Roche to continue their plans to aggressively study ITMN-191 in this difficult to treat population and provided an important insight to the range of doses to explore in future studies.

-- Pharmacokinetic (pk) and Pharmacodynamic (pd) Results in the Phase 1b MAD Study (Poster #1861): ITMN-191 was intentionally designed to achieve a high liver-to-plasma ratio in HCV patients in order to reduce any potential side effects associated with systemic circulation of drug. Poster #1861 shows that the strong viral kinetic results reported in abstract #1847 were associated with very low plasma concentrations, achieving the key objective of a high liver-to-plasma ratio in patients infected with HCV. The pharmacokinetics of ITMN-191 in mono-therapy were more than dose proportional at higher doses.

Results of In Vitro Combinations of ITMN-191 plus direct anti-virals in HCV models

-- Two Experiments of the Combination of ITMN-191 with HCV Polymerase Inhibitors R7128 and R1626 (Poster #1885): ITMN-191 was combined separately with two polymerase inhibitors, R7128 (Roche/Pharmasset) and R1626 (Roche) in two assays. One assay modeled HCV replication (14-day replicon clearance assay) and the other assay modeled viral resistance (a 3-week colony formation assay model). The combination of ITMN-191 with the active moeity of either R7128 or R1626 resulted in significantly enhanced clearance of the HCV replicon and reduced or suppressed the emergence of drug-resistant viral variants.

This work was carried out in anticipation of future clinical studies using ITMN-191 with either R7128 or R1626, and demonstrates that such combinations would likely result in significantly greater antiviral activity than has been observed with any of these agents in previous monotherapy trials.

Current Development of ITMN-191

Based on the encouraging results reported in the above studies, in late May 2008 InterMune initiated an ongoin
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
2. InterMune to Present at Canaccord Adams Conference
3. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
4. InterMune to Present at BMO Healthcare Conference
5. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
6. InterMune to Present at Jefferies Healthcare Conference
7. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
8. InterMune to Present at Citigroup Healthcare Conference
9. InterMune to Present at Bank of America Health Care Conference
10. InterMune to Present at Deutsche Bank Health Care Conference
11. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... July 03, 2015 , ... The global failure analysis ... from 2015 to 2020. The bioscience market is expected to grow at the highest ... of failure analysis equipment in the research labs and academic institutions for root cause ...
(Date:7/2/2015)... ... ... in countless labs for decades. In the past, people had to go to a ... a daunting and tiring process looking at endless data tables and charts. Often time’s, ... catalog structure. , Now thanks to FireflySci, scientists are throwing away those old books and ...
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech ... surgical instruments in Orthopedics, announced today the acquisition of Turner Medical, Inc ... provider of surgical instruments to the Spine Industry. The acquisition of Turner Medical ...
(Date:7/1/2015)... BANGALORE, India , July 1, 2015 ... that uses next generation sequencing technology to empower cancer ... Storrer as chief executive officer. In his expanded ... responsible for all strategy, business expansion and worldwide operations ... served as Strand,s chairman and CEO since its founding ...
Breaking Biology Technology:Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5New Cuvette E-Commerce Website Launched by FireflySci 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3
... New Mexico, February 10, 2009A team of Los Alamos ... multiplicationwhen a photon creates multiple electronsis a real phenomenon ... born of extraneous effects that mimic carrier multiplication. The ... of Chemical Research , shows the possibility of solar ...
... 10 Johnson & Johnson Pharmaceutical Research & ... and Drug Administration (FDA) has asked for additional ... (sNDA) for RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection. The ... RISPERDAL(R) CONSTA(R) for adjunctive maintenance treatment to delay ...
... FRANCISCO, Feb. 10 Jennerex, Inc. (San Francisco, ... that the journal, Nature Reviews Cancer, has published ... oncolytic poxviruses, which have,demonstrated encouraging clinical and preclinical ... issue, was authored by David H. Kirn, M.D.,president ...
Cached Biology Technology:Research highlights potential for improved solar cells 2Research highlights potential for improved solar cells 3FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder 2FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder 3FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder 4FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder 5Nature Reviews Publishes Article About Jennerex's Multi-Mechanistic Cancer Therapeutic 2Nature Reviews Publishes Article About Jennerex's Multi-Mechanistic Cancer Therapeutic 3
(Date:6/23/2015)... June 23, 2015   MedNet Solutions , ... the entire spectrum of clinical research, is pleased ... ™ , the company,s intuitive, flexible and affordable ... Silver 2015 Stevie® Award by the American ... Services Website category.  The American Business Awards are ...
(Date:6/18/2015)... -- This report analyzes the worldwide markets for Immunoassay ... which includes Immunoassay Analyzers and Reagents: Enzyme Immunoassay Systems, ... and Nephelometric Immunoassay Systems. The report provides separate comprehensive ... Japan , Europe ... America , and Rest of World. Annual estimates ...
(Date:6/17/2015)... Calif. , June 17, 2015  Synaptics ... human interface solutions, today announced that Xiaomi, one ... the Synaptics ® ClearPad ® family ... display driver integrated circuits (DDICs) for its latest ... By leveraging ClearPad for full in-cell display solutions ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3
... 2013 Listed below are the selected highlights for the ... Genetics . The March issue is available online ... Vol. 193, MARCH 2013, Copyright 2013. Please feel ... these articles on cellular genetics; population and evolutionary genetics; genome ...
... AURORA, Colo. (March 5, 2013) Researchers have discovered that ... obese even on a high fat diet, a finding they ... diet that induces obesity these mice don,t get fat," said ... vice-chairman of research for Obstetrics and Gynecology at the University ...
... the Nordic EMBL Partnership for Molecular Medicine celebrates two ... an extended period of 10 years, and the expansion ... of the Danish Research Institute of Translational Neuroscience (DANDRITE) ... The Nordic EMBL Partnership for Molecular Medicine was initiated ...
Cached Biology News:Genetics Society of America's Genetics journal highlights for March 2013 2Genetics Society of America's Genetics journal highlights for March 2013 3Genetics Society of America's Genetics journal highlights for March 2013 4Researchers discover gene that causes obesity in mice 2Denmark joins the Nordic EMBL Partnership for Molecular Medicine 2
...
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Goat polyclonal to Duffy / FY / DARC...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: